In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)

In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham’s Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions.  The class also includes direct purchasers of generic versions of Lamictal from Teva, SmithKline’s co-defendant and alleged co-conspirator.  The complaint alleges that SmithKline entered a reverse payment patent settlement with Teva to delay launching its first filed generic to compete with  SmithKline’s $2 billion a year Lamictal Tablets.  Such an agreement violates §§ 1 and 2 of the Sherman Act.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.


Filed on 11/12/2015


685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331


Joseph T. Lukens Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331


1901 Avenue of the Stars Suite 1060
Los Angeles, California 90067
(424) 256-2884
(424) 256-2885


3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534


1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania